Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,388 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,388 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07173101 | Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on…(HEADBAND) | Phase 2 | terminated | Sep 15, 2025 | University of Utah | Safety Review | Safety / toxicity |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | withdrawn | Feb 4, 2026 | Thomas Jefferson University | FDA requested significant changes to the study protocol | Other (stated, no rule matched) |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT05842031 | Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal… | — | suspended | May 3, 2023 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05904899 | An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New… | — | suspended | Jun 15, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06052345 | Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors,…(CIPN-REBECCA) | — | withdrawn | Sep 25, 2023 | Theodoros Foukakis | No accrual | Enrollment / accrual |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | Phase 1 | withdrawn | Nov 10, 2021 | Guizhou Bailing Group Pharmaceutical Co Ltd | Withdrawn due to duplicate registration | Other (stated, no rule matched) |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to… | — | terminated | Aug 12, 2024 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2024 | Kevin McNerney | The trial has been stopped pending FDA approval of modifications to the trial protocol. | Other (stated, no rule matched) |
| NCT02393833 | IBCSG Trial 22-00 Serum Substudy | N/A | terminated | Mar 19, 2015 | ETOP IBCSG Partners Foundation | Sufficient statistical power cannot be met due to low samples size | Other (stated, no rule matched) |
| NCT04007640 | Early Screening of Pancreatic Lesions : Development of New Imaging Tools(PAIR-PANCREAS) | N/A | terminated | Jul 5, 2019 | Assistance Publique - Hôpitaux de Paris | Population difficult to recruit; number of enrolled patients sufficient for analyses. | Enrollment / accrual |
| NCT04017819 | Biodistribution & Pharmacokinetic of Position Emission Tomography (PET)… | Phase 1 | suspended | Jul 12, 2019 | Stanford University | funding | Funding |
| NCT04605614 | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | Phase 1 | withdrawn | Oct 28, 2020 | City of Hope Medical Center | slow accruals | Enrollment / accrual |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… | Phase 2 | terminated | Apr 4, 2022 | Providence Health & Services | PI opted to close study due to poor accrual. | Enrollment / accrual |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT06162663 | Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for… | Phase 4 | terminated | Dec 8, 2023 | Medical University of South Carolina | Terminated early due to insufficient accrual to meet prespecified statistical analysis requirements. | Enrollment / accrual |
| NCT06489769 | Opioid Misuse in Patients With Cancer | — | suspended | Jul 8, 2024 | Rigshospitalet, Denmark | Enrollment suspended due to insufficient recruitment resulting from staffing shortages and… | Enrollment / accrual |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | N/A | withdrawn | Sep 24, 2024 | Scripps Health | no patients were able to be enrolled | Enrollment / accrual |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered… | Phase 1 | terminated | Nov 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05591092 | Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular… | — | terminated | Oct 24, 2022 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors… | Phase 1 / Phase 2 | terminated | Apr 30, 2024 | Genmab | Terminated due to strategic decision | Sponsor / business decision |
| NCT03164460 | Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in… | Phase 2 | suspended | May 23, 2017 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid… | Phase 1 / Phase 2 | terminated | Sep 17, 2020 | Tianhong Li | Terminated early by the Sponsor due to business reason. | Sponsor / business decision |
| NCT05201014 | Cancer Survivor Cardiomyopathy Detection(CASCADE) | — | terminated | Jan 21, 2022 | Mayo Clinic | diminished funding | Funding |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… | Phase 1 | suspended | Jul 9, 2024 | Fred Hutchinson Cancer Center | Recruitment on hold with plans to open to accrual again soon. | Enrollment / accrual |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT05065736 | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase… | Early Phase 1 | terminated | Oct 4, 2021 | Roberto Vargas | Funding unavailable | Funding |
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | Phase 2 | suspended | Oct 20, 2017 | Dana-Farber Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | Phase 2 | terminated | Jun 19, 2019 | Gregory Daniels | Lack of funding | Funding |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph… | Phase 2 | terminated | Jan 9, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV… | Phase 2 | terminated | Aug 26, 2020 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… | Phase 2 | terminated | Aug 6, 2021 | Fred Hutchinson Cancer Center | The study was closed due to the end of funding. | Funding |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT07165756 | "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the…(MaVie) | — | terminated | Sep 10, 2025 | Institut de Cancérologie de Lorraine | Principal Investigator's departure | Investigator |
| NCT00799110 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With… | Phase 2 | terminated | Nov 27, 2008 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT04539366 | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children,… | Phase 1 | suspended | Sep 7, 2020 | National Cancer Institute (NCI) | Other - review of safety data | Safety / toxicity |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years… | Phase 2 | withdrawn | Apr 1, 2025 | Memorial Sloan Kettering Cancer Center | Lack of funding | Funding |
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | Phase 1 | withdrawn | Mar 3, 2016 | Abramson Cancer Center at Penn Medicine | Covid-19 | COVID-19 / pandemic |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT05995236 | Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy | — | terminated | Aug 16, 2023 | Methodist Health System | So far, we have not been able to collect meaningful data for these patients which also led to our… | Other (stated, no rule matched) |
| NCT07075627 | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic… | — | withdrawn | Jul 20, 2025 | Addario Lung Cancer Medical Institute | Sponsor/Funder decision | Other (stated, no rule matched) |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients… | Phase 1 | suspended | Nov 11, 2016 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials